Bayer's Roundup Win Gets a Split Verdict From the Analyst Community
Published on 11/02/2026 at 21:40 | Editorial boerse-global.de
A Missouri jury handed Bayer a unanimous victory on Friday in the Roundup litigation brought by three women, and the market's reaction has already come and gone. After the verdict drove a sharp rally in the stock, the shares gave back ground at the start of the new week, with reports putting the decline at somewhere between 0.8% and 1.1%.
The case, heard in St. Louis, was the first glyphosate trial since the US Supreme Court's ruling in June, according to Reuters. Bayer says the plaintiffs failed on their remaining grounds once that precedent was in place — the company's reading being that the other side could produce no evidence to support alternative theories of liability. It was that courtroom outcome, delivered Friday, that set off the initial jump in the share price.
Two Houses, Two Conclusions
The analyst fraternity emerged from the verdict more divided than the jury. JPMorgan kept Bayer at "Overweight" with a price target of 61 euros on Friday, with analyst Richard Vosser framing the result as one more step toward containing the glyphosate litigation and predicting a positive share-price response. Jefferies, by contrast, stuck with "Hold" and a 46-euro target. Analyst Michael Leuchten called the trial win encouraging but pointed to the judicial approval still outstanding for the proposed settlement of the mass claims.
Should investors sell immediately? Or is it worth buying Bayer?
mwb research took the most bullish line of the three, reaffirming its buy recommendation and a price target of 65.00 EUR on Friday. The verdict in Monsanto's favour, in the research house's view, has strengthened Bayer's legal position in the Roundup dispute.
The Operating Story Steps Back Into View
With the legal headlines fading, attention turned back to the business itself. Media coverage ahead of the upcoming quarterly update put the emphasis on expectations for operating performance and on progress in cutting debt — though no single fresh catalyst was identified for Monday's pullback, and no concrete link between those themes and the day's trading has been established.
Bayer has scheduled its third-quarter 2026 interim report for 3 November 2026, with the release set for 7:30 a.m. CET. A live video broadcast of the media update is slated for 10:00 a.m., and an investor video call will follow at 2:00 p.m. CET the same day.
A Pipeline Datapoint Worth Remembering
Roughly a week before the verdict, Bayer reported positive results from an interim analysis of the Phase III DASL-HiCaP study. Darolutamide, added to ADT and radiotherapy, cut the risk of metastases or death by 58% versus placebo in patients at high risk of recurrence. The four-year metastasis-free survival rate came in at 95% on darolutamide against 88% in the placebo arm, according to the company.
Ad
Bayer Stock: New Analysis - 2 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
